Shares of Arbutus Biopharma Corp. (NASDAQ:ABUS) rose 5.1% on Monday . The stock traded as high as $3.97 and last traded at $3.93, with a volume of 63,716 shares trading hands. The stock had previously closed at $3.74.

ABUS has been the subject of several recent research reports. Wedbush restated an “outperform” rating and issued a $20.00 price objective on shares of Arbutus Biopharma Corp. in a report on Wednesday, July 20th. Chardan Capital downgraded Arbutus Biopharma Corp. from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $3.25 to $2.75 in a report on Friday, July 8th. Zacks Investment Research upgraded Arbutus Biopharma Corp. from a “sell” rating to a “hold” rating in a report on Thursday, August 18th. Leerink Swann restated a “buy” rating on shares of Arbutus Biopharma Corp. in a report on Wednesday, July 20th. Finally, William Blair restated an “outperform” rating on shares of Arbutus Biopharma Corp. in a report on Sunday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $9.39.

The company’s market cap is $220.28 million. The stock’s 50-day moving average is $4.00 and its 200-day moving average is $3.98.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.36. Equities research analysts expect that Arbutus Biopharma Corp. will post ($3.35) EPS for the current fiscal year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.